TIDMPYC

RNS Number : 7779T

Physiomics PLC

22 July 2020

22 July 2020

Physiomics plc

("Physiomics") or ("the Company")

Share Price Movement

The Board of Physiomics plc (AIM: PYC), a provider of technology-based solutions to predict the effects of cancer treatment regimens for the biopharma industry, notes the recent rise in the Company's share price and trading volumes and advises the market that it knows of no specific reason for such significant movements.

Further to its announcements of 27 May 2020 and 30 June 2020, the Company remains in the late stages of finalising a contract with the potential new large pharmaceutical client. While there is no guarantee that the contract will be entered into, the commercial terms have been agreed and the directors are confident it will be signed in the coming weeks. Should the contract be entered into, the project would take two of our technical staff around five months to complete. Further updates will be provided as and when appropriate in due course.

This announcement is released by Physiomics plc and contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 (MAR), and is disclosed in accordance with the Company's obligations under Article 17 of MAR.

Enquiries:

Physiomics plc

Dr Jim Millen, CEO

+44 (0)1865 784 980

Strand Hanson Ltd (NOMAD)

Richard Tulloch & James Dance

+44 (0)20 7409 3494

Hybridan LLP (Broker)

Claire Louise Noyce

+44 (0)20 3764 2341

Notes to Editor

About Physiomics

Physiomics(R) is an oncology consultancy using mathematical models and its Virtual Tumour(TM) technology to support the development of cancer treatment regimens and personalised medicine solutions. The predictive capability of Virtual Tumour has been confirmed by 55 projects, involving over 25 targets and 60 drugs, and has worked with clients such as Merck KGaA, Merck & Co, Bayer and Lilly.

Based in Oxford UK, the Company works with clients worldwide to support their pre-clinical and clinical oncology development programs. Its team of scientists and computer modelling experts provide bespoke solutions encompassing data, analytics and insight.

Physiomics senior management has academic and commercial expertise, including over 90 years collectively of working in oncology and/or computational biology and over 100 publications in peer reviewed journals.

For more information please visit:

www.physiomics-plc.com

www.twitter.com/Physiomics

www.linkedin.com/company/physiomics-plc/

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

SPMFLFSIDIIFFII

(END) Dow Jones Newswires

July 22, 2020 06:45 ET (10:45 GMT)